Kathleen M Egan
Overview
Explore the profile of Kathleen M Egan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
3595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ellison G, Helzlsouer K, Rosenfield S, Kim Y, Ashare R, Blaes A, et al.
J Natl Cancer Inst Monogr
. 2024 Aug;
2024(66):202-217.
PMID: 39108244
Background: The legal climate for cannabis use has dramatically changed with an increasing number of states passing legislation legalizing access for medical and recreational use. Among cancer patients, cannabis is...
2.
Islam J, Nguyen O, Turner K, Martinez Y, Rodriguez O, Rodriguez D, et al.
J Natl Cancer Inst Monogr
. 2024 Aug;
2024(66):224-233.
PMID: 39108241
Background: Although substance use may have adverse impacts on cancer outcomes, little is known regarding patterns of concurrent substance use with cannabis among cancer patients. Our objective was to examine...
3.
Gonzalez B, Li X, Martinez Y, Jim H, Oswald L, Islam J, et al.
J Natl Cancer Inst Monogr
. 2024 Aug;
2024(66):259-266.
PMID: 39108234
Background: Patients with cancer report increasing rates of cannabis use, often to manage symptoms and toxicities. The efficacy and safety of cannabis, however, for some use cases remains unclear. To...
4.
Turner K, Nguyen O, Islam J, Rajasekhara S, Martinez Y, Tabriz A, et al.
J Natl Cancer Inst Monogr
. 2024 Aug;
2024(66):298-304.
PMID: 39108232
Background: There has been limited study regarding patient-provider communication about medical cannabis for cancer symptom management. To address this gap, this study assesses the determinants and prevalence of patient-provider communication...
5.
Mokhtari S, Peeri N, Beer-Furlan A, Anderson M, Chowdhary S, LaRocca R, et al.
Br J Neurosurg
. 2023 Jun;
:1-4.
PMID: 37287223
Purpose: We studied 571 patients with intracranial meningioma for clinical characteristics and tumor location associated with high grade meningioma (WHO II/III). Materials And Methods: Patients were participants in a multicentre...
6.
Yaghjyan L, Mai V, Darville L, Cline J, Wang X, Ukhanova M, et al.
Cancer Causes Control
. 2023 Jun;
34(10):873-881.
PMID: 37286847
Purpose: The gut microbiome is a potentially important contributor to endogenous estrogen levels after menopause. In healthy postmenopausal women, we examined associations of fecal microbiome composition with levels of urinary...
7.
Alban T, Grabowski M, Otvos B, Bayik D, Wang W, Zalavadia A, et al.
JCI Insight
. 2023 May;
8(13).
PMID: 37252795
Intratumoral heterogeneity is a defining hallmark of glioblastoma, driving drug resistance and ultimately recurrence. Many somatic drivers of microenvironmental change have been shown to affect this heterogeneity and, ultimately, the...
8.
Cote D, Stampfer M, Egan K
Cancer Epidemiol
. 2022 Mar;
78:102126.
PMID: 35303619
No abstract available.
9.
Coghill A, Kim Y, Hodge J, Bender N, Smith-Warner S, Teras L, et al.
Int J Cancer
. 2022 Feb;
151(2):222-228.
PMID: 35225352
Glioma is an aggressive neoplasm of the brain with poorly understood etiology. A limited number of pathogens have been examined as glioma risk factors, but data from prospective studies with...
10.
Samanic C, Teer J, Thompson Z, Creed J, Fridley B, Nabors L, et al.
Mitochondrion
. 2022 Jan;
63:32-36.
PMID: 35032707
Background: Malignant gliomas are the most common primary adult brain tumors, with a poor prognosis and ill-defined etiology. Mitochondrial DNA (mtDNA) sequence variation has been linked with certain cancers; however,...